Browsing by Subject "Advanced cancer"
Now showing items 41-52 of 52
-
Article
Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx
(2012)Angiogenesis is active in localised laryngeal squamous cell carcinoma. We assessed relative messenger RNA (mRNA) and immunohistochemical (IHC) expression of Vascular Endothelial Growth Factors (VEGF) A, B, C, their receptors ...
-
Article
Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy
(1996)Possible prognostic variables for tumor response, time to progression (TTP), and survival in 141 patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy were analyzed. None of ...
-
Article
Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: Biases and evolution over time
(2003)We systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42 661 patients), no regimens were compared in ...
-
Article
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
(1997)Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April ...
-
Article
Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma
(1996)The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals ...
-
Article
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
(2007)Background: Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental ...
-
Article
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
(2006)Background: Aromatase inhibitors and inactivators have been extensively tested in patients with advanced breast cancer, but it is unclear whether they offer any survival benefits compared with standard hormonal treatment ...
-
Article
Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer
(2002)Background: The usefulness of tumor volumetry in ovarian epithelial cancer has never been intensively investigated. The aim of the present study was to determine the value of quantitative analysis of tumor volume as a ...
-
Article
Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma: Results of two phase II clinical trials
(2002)Background: The aim of this study is firstly to determine the response rates and toxicity of two regimens containing vinblastine (VBL) in combination with interferon-gamma (IFN-γ) in the treatment of patients with advanced ...
-
Article
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2
(2012)Aim: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. Patients and Methods: The ...
-
Article
Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy
(2007)Background: Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine ...
-
Article
Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors
(2004)Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...